A Multi-center, Phase I/II Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pancreatic Cancer.

Trial Profile

A Multi-center, Phase I/II Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Refametinib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BAGPAC
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Dec 2016 Results assessing safety and efficacy published in the Targeted Oncology.
    • 15 Apr 2015 According to a Bayer HealthCare media release, data from this study presented at the American Association for Cancer Research (AACR) 106th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top